Compound K, an intestinal metabolite of ginsenosides, inhibits PDGF-BB-induced VSMC proliferation and migration through G1 arrest and attenuates neointimal hyperplasia after arterial injury

Atherosclerosis. 2013 May;228(1):53-60. doi: 10.1016/j.atherosclerosis.2013.02.002. Epub 2013 Feb 18.

Abstract

Objective: Compound K (CK), an intestinal metabolite of ginsenosides, has pharmacological properties such as anti-angiogenesis, anti-inflammation, anti-platelet and anti-cancer activities. In the present study, we investigated the inhibitory effect of CK on vascular smooth muscle cell (VSMC) proliferation and migration in vitro and neointima formation in a rat carotid artery injury model.

Results: CK significantly inhibited both the proliferation and migration of PDGF-BB-stimulated VSMCs in a concentration-dependent manner. In accordance with these findings, CK blocked the PDGF-BB-induced progression of synchronized cells through the G0/G1 phase of the cell cycle. CK also decreased the expressions of cell cycle-related proteins, including cyclin-dependent kinase (CDK) 2, cyclin E, CDK4, cyclin D1, and proliferative cell nuclear antigen (PCNA) in response to PDGF. However, CK did not affect early signal transduction through PDGF-Rβ, Akt, ERK1/2 and PLC-γ1 phosphorylation. CK attenuated PDGF-BB-induced VSMC migration by inhibiting MMP-2 and MMP-9 expression. Furthermore, the CK-treated groups showed a significant reduction in neointima formation vs. the control group. Immunohistochemical staining demonstrated decreased expression of PCNA in the neointima of the CK-treated group.

Conclusion: Our findings demonstrated that CK was capable of suppressing the abnormal VSMC proliferation and migration. It suggested that CK can be a therapeutic agent to control pathologic cardiovascular conditions such as restenosis and atherosclerosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angioplasty, Balloon / adverse effects
  • Animals
  • Becaplermin
  • Carotid Artery Injuries / drug therapy*
  • Carotid Artery Injuries / metabolism
  • Carotid Artery Injuries / pathology
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • G1 Phase Cell Cycle Checkpoints / drug effects
  • Ginsenosides / chemistry
  • Ginsenosides / pharmacokinetics*
  • Ginsenosides / pharmacology
  • MAP Kinase Signaling System / drug effects
  • Muscle, Smooth, Vascular / cytology*
  • Neointima / drug therapy*
  • Neointima / metabolism
  • Neointima / pathology
  • Phospholipase C gamma / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Proto-Oncogene Proteins c-sis / antagonists & inhibitors*
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Platelet-Derived Growth Factor beta / metabolism

Substances

  • Ginsenosides
  • Proto-Oncogene Proteins c-sis
  • Becaplermin
  • ginsenoside M1
  • Receptor, Platelet-Derived Growth Factor beta
  • Akt1 protein, rat
  • Proto-Oncogene Proteins c-akt
  • Phospholipase C gamma